News | Structural Heart | January 04, 2024

Laguna Tech USA Announces Site Record Number of Transcatheter Heart Valves Implanted at Single Center on Same Day in First-in-Human Clinical Trial

Five implants successfully accomplished at the Instituto Nacional de Torax in Santiago, Chile with advanced engineered heart valve, ZETA, designed to provide flexibility and optionality regardless of high, low or zero calcification

Five implants successfully accomplished at the Instituto Nacional de Torax in Santiago, Chile with advanced engineered heart valve, ZETA, designed to provide flexibility and optionality regardless of high, low or zero calcification

Getty Images


January 4, 2024 — Laguna Tech USA, a privately-held medical technology company dedicated to innovations in structural heart solutions to broaden useability and applicability for patients, today announced that a record number five patients were successfully treated at a single center on the same day with the ZETA Balloon Expandable Aortic Valve System to treat aortic valve disease. In all cases, patients achieved complete resolution of aortic disease with no residual stenosis or regurgitation immediately following the procedure, and all patients were discharged within 24-48 hours of the procedure. The high volume of procedures was made possible due to the versatility and flexibility of the novel design of the ZETA system, which provides greater ease of implantability for a broader patient population than currently approved valve systems. All five implants were accomplished on the same day at the Instituto Nacional de Torax in Santiago, Chile within the ongoing feasibility trial for the ZETA system.

The ZETA system is a novel balloon-expandable transcatheter valve with six expanding arms and a low profile covered delivery system.

Dr. Christian Dauvergne, Chief of Interventional Cardiology, Instituto Nacional de Torax, added, “Our ability to successfully implant the ZETA Aortic Valve in five patients with complex, diverse clinical profiles on a single day was due to the very simple and efficient design characterized by a low profile and straightforward transcatheter system, which allows for simple, advantageous placement in the heart. I look forward to the continued development of the ZETA device to explore the potential of this breakthrough technology to treat more patients with aortic regurgitation with unmet needs.”

The lead primary investigator, Dr. Scott Lim, a cardiologist from the University of Virginia noted, “The treatment of complex and diverse aortic valve disease patients at the center in Santiago was an impressive accomplishment, as was the highly reproducible landing of the ZETA valve relative to the aortic annulus, regardless of the degree or lack of calcium, which speaks to the potential of the balloon-expandable ZETA Aortic Valve. We treated patients both with severe, non-calcific aortic regurgitation as well as those with highly calcific aortic stenosis, and in all cases there was no paravalvar regurgitation. Additionally, by fluoroscopy, all implanted ZETA valves were consistently implanted within two millimeters of the annulus. I look forward to the upcoming pivotal clinical trials on the ZETA valve.”

“We are thrilled with this significant and rapid progress in the development of the ZETA valve,” said Gilbert Madrid, chief executive officer of Laguna Tech USA. “Together with the encouraging data we have generated with our other device, the ALPHA valve and its successful implants, we are making important advancements in realizing the promise of our next-generation, differentiated aortic valves. With two varying valve designs, each leveraging advanced technology and engineering of existing products on the market, we look forward to the potential of our technology to significantly expand the number of patients with aortic valve regurgitation who may be treated with our minimally invasive treatment options. We look forward to scaling this technology and moving into later stage clinical development so we can bring this technology to a greater population of patients.”

For more information: https://lagunatechventures.com/


Related Content

News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
News | Heart Valve Technology

Jan. 25, 2025—A new study presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that ...

Home January 27, 2025
Home
News | Heart Valve Technology

Jan. 6, 2025 — Medtronic plc has announced it received CE (Conformité Européenne) Mark for the Harmony Transcatheter ...

Home January 06, 2025
Home
News | Heart Valve Technology

Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid ...

Home September 04, 2024
Home
News | Heart Valve Technology

June 27, 2024 — The sheer scale of undiagnosed heart valve disease in our aging population has been revealed for the ...

Home June 27, 2024
Home
News | Heart Valve Technology

June 21, 2024 — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed ...

Home June 21, 2024
Home
News | Heart Valve Technology

June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial ...

Home June 10, 2024
Home
News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
Subscribe Now